NDAORALTABLETPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Poly(ADP-Ribose) Polymerase Inhibitors
Pharmacologic Class:
Poly(ADP-Ribose) Polymerase Inhibitor
Clinical Trials (5)
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Started Sep 2025
50 enrolled
Endometrial Cancer
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
Started Aug 2025
33 enrolled
High Grade Serous Ovarian Cancer
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
Started May 2025
150 enrolled
Endometrial Cancer
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Started Feb 2025
85 enrolled
Metastatic Castration-resistant Prostate Cancer
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
Started Feb 2025
20 enrolled
Pancreatic Cancer
Loss of Exclusivity
LOE Date
Oct 25, 2041
190 months away
Patent Expiry
Oct 25, 2041
Exclusivity Expiry
May 8, 2027